158 related articles for article (PubMed ID: 37704931)
21. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
[TBL] [Abstract][Full Text] [Related]
23. ACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
[TBL] [Abstract][Full Text] [Related]
24. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
25. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
[TBL] [Abstract][Full Text] [Related]
26. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic performance of texture analysis on MRI in grading cerebral gliomas.
Skogen K; Schulz A; Dormagen JB; Ganeshan B; Helseth E; Server A
Eur J Radiol; 2016 Apr; 85(4):824-9. PubMed ID: 26971430
[TBL] [Abstract][Full Text] [Related]
29. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
30. Expression of FAS-L Differs from Primary to Relapsed Low-grade Gliomas and Predicts Progression-free Survival.
Werner JM; Kuhl S; Stavrinou P; Röhn G; Krischek B; Blau T; Goldbrunner R; Timmer M
Anticancer Res; 2017 Dec; 37(12):6639-6648. PubMed ID: 29187439
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma.
Pang C; Guan Y; Zhao K; Chen L; Bao Y; Cui R; Li G; Wang Y
Int J Clin Exp Pathol; 2015; 8(5):4943-52. PubMed ID: 26191187
[TBL] [Abstract][Full Text] [Related]
32. Multi-omics landscape of circadian rhythm pathway alterations in Glioma.
Zhang C; Xu J; Chen L; Lin X
Bioengineered; 2021 Dec; 12(1):3294-3308. PubMed ID: 34224318
[TBL] [Abstract][Full Text] [Related]
33. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
34. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
35. Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.
Röhrich M; Huang K; Schrimpf D; Albert NL; Hielscher T; von Deimling A; Schüller U; Dimitrakopoulou-Strauss A; Haberkorn U
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1573-1584. PubMed ID: 29732524
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
[TBL] [Abstract][Full Text] [Related]
37. MicroRNAs as efficient biomarkers in high-grade gliomas.
Barciszewska AM
Folia Neuropathol; 2016; 54(4):369-374. PubMed ID: 28139816
[TBL] [Abstract][Full Text] [Related]
38. Death Receptor 6 as a Prognostic Marker in Low-grade Glioma.
Stegmann SK; Kuhl S; Im NG; Diem-Dinh DT; Goertz L; Goldbrunner R; Timmer M
Anticancer Res; 2022 Mar; 42(3):1237-1245. PubMed ID: 35220214
[TBL] [Abstract][Full Text] [Related]
39. Benign Glioma.
Wu PB; Filley AC; Miller ML; Bruce JN
Adv Exp Med Biol; 2023; 1405():31-71. PubMed ID: 37452934
[TBL] [Abstract][Full Text] [Related]
40. Tissue Proteome Analysis of Different Grades of Human Gliomas Provides Major Cues for Glioma Pathogenesis.
Gollapalli K; Ghantasala S; Atak A; Rapole S; Moiyadi A; Epari S; Srivastava S
OMICS; 2017 May; 21(5):275-284. PubMed ID: 28481733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
